"Adalimumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.
| Descriptor ID |
D000068879
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.250 D12.776.124.790.651.114.224.060.250 D12.776.377.715.548.114.224.200.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adalimumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Adalimumab [D12.776.124.486.485.114.224.060.250]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Adalimumab [D12.776.124.790.651.114.224.060.250]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Adalimumab [D12.776.377.715.548.114.224.200.250]
Below are MeSH descriptors whose meaning is more specific than "Adalimumab".
This graph shows the total number of publications written about "Adalimumab" by people in this website by year, and whether "Adalimumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2009 | 0 | 4 | 4 |
| 2011 | 0 | 4 | 4 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 42 | 18 | 60 |
| 2018 | 26 | 33 | 59 |
| 2019 | 14 | 9 | 23 |
| 2020 | 5 | 5 | 10 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adalimumab" by people in Profiles.
-
Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease. J Crohns Colitis. 2022 Feb 23; 16(2):190-198.
-
Anterior Scleritis Manifesting After Coronavirus Disease 2019: A Report of Two Cases. Cornea. 2021 Sep 01; 40(9):1204-1206.
-
Switching infliximab in psoriatic patients during COVID-19 pandemics: A real-life retrospective study comparing intra-versus interclass switching strategies. Dermatol Ther. 2021 Sep; 34(5):e15088.
-
May COVID-19 infection induce a paradoxical improvement of a non-responsive case of hidradenitis suppurativa? Ital J Dermatol Venerol. 2021 Oct; 156(5):616-617.
-
Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial. Int Immunopharmacol. 2021 Oct; 99:107961.
-
SARS-COV-2 infection might cause transient cutaneous lesions in IBD patients under treatment with adalimumab. J Gastrointestin Liver Dis. 2021 06 19; 30(2):310-311.
-
Anti-COVID-19 measurements for hidradenitis suppurativa patients. Exp Dermatol. 2021 06; 30 Suppl 1:18-22.
-
Safety of Biological Therapy in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2021 05 01; 72(5):736-741.
-
Impact of Treatment With TNF-a Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic. J Cutan Med Surg. 2021 Jul-Aug; 25(4):446-448.
-
Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig Liver Dis. 2021 03; 53(3):277-282.